Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Results
-
Joint Development of Therapeutic Cancer Vaccine WT4869
[PDF 73KB] -
Organizational Restructuring and Personnel Changes
[PDF 176KB] -
Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®,
[PDF 137KB]
Filed for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C -
Personnel Changes
[PDF 168KB] -
Revision of Financial Outlook for Fiscal Year 2010
[PDF 43KB]
(January 1 - December 31, 2010) -
Relief Efforts Support for the Serious Flood Disaster Area in Pakistan
[PDF 122KB] -
Data Presented at the American Society for Bone and Mineral Research
[PDF 169KB]
on Japanese Phase III Study of 'Eldecalcitol,' an Active Vitamin D3 Derivative -
ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe for the treatment of systemic Juvenile Idiopathic Arthritis
[PDF 260KB] -
Chugai’s Novel Antibody Engineering Technology Published in Nature Biotechnology
[PDF 333KB] -
Introduction of a Personnel Program to Provide Contract Workers with Opportunities to Change to Full Employment
[PDF 171KB] -
F. Hoffmann-La Roche Announces Third Quarter Sales 2010
[PDF 21KB] -
Supply Plan of "Tamiflu®" Anti-influenza Drug
[PDF 171KB] -
Contribution of Para-transit Vehicles to Welfare Services
[PDF 219KB] -
Chugai Presents an Anti-Cancer Charity “Medicine and Humor”
[PDF 199KB] -
Information about Plan to Appoint a New Accounting Auditor
[PDF 83KB] -
Trial Use of Electric Vehicles - Enhancement of Preventive Measures Against Global Warming -
[PDF 189KB] -
Anti-Angiogenic Anti-Cancer Agent Avastin® Condition for Approval (All Patients Surveillance) Removed in Japan
[PDF 178KB] -
Anti-Cancer Agent, Xeloda® Filed for Advanced or Refractory Gastric Cancer By “New Drug Application Based on Evidence in the Public Domain”
[PDF 168KB] -
Renewal of “Cancer Information Guide,” a Website for Patients: - Maximizing Convenience through Unique Built-in Search Engine -
[PDF 157KB] -
Awareness Enhancement of Colon Diseases with Display of Giant-Sized Balloon Art, "Japanese Version of a Giant Colon"
[PDF 260KB] -
Organizational Restructuring and Personnel Changes
[PDF 139KB] -
"ACTEMRA®" Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Conditions for Approval (All Patients Surveillance) Lifted in Japan
[PDF 196KB] -
Assisting Work-Life Balance
[PDF 201KB] -
New Interactive Videos at Permanent Exhibit "Dr. Kitanomaru's Bio Pharmaceutical Laboratory" at the Science Museum
[PDF 234KB] -
F. Hoffmann-La Roche Announces 2010 Half Year Results
[PDF 13KB] -
Support for Areas Affected by Foot-and-Mouth Disease in Miyazaki Prefecture
[PDF 131KB] -
Anti-Cancer Agent, Herceptin® Designated for Priority Review by Ministry of Health, Labour and Welfare
[PDF 194KB] -
Recombinant Human Erythropoietin,“EPOGIN® Subcutaneous Injection Syringe 24000,” Approved in Japan
[PDF 187KB] -
RoACTEMRA: New Hope for Children with Systemic Juvenile Idiopathic Arthritis
[PDF 275KB] -
“Transformation in Medical Care & Rheumatoid Arthritis” Chugai Holds an Educational Event at Yurakucho Mullion, Tokyo
[PDF 163KB] -
New Licence Extension for RoACTEMRA in Europe
[PDF 186KB] -
Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
[PDF 84KB] -
RoACTEMRA Recommended for Approval in Europe for the Reduction of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
[PDF 200KB] -
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 78KB] -
F. Hoffmann-La Roche Announces First Quarter Sales 2010
[PDF 64KB] -
Anti-Cancer Agents, Herceptin® and Xeloda® Filed for HER2-positive Advanced or Recurrent Gastric Cancer
[PDF 180KB] -
ACTEMRA(tocilizumab) filed in the US for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
[PDF 180KB] -
Chugai to In-license Hedgehog Pathway Inhibitor “RG3616”
[PDF 177KB] -
Personnel Changes
[PDF 177KB] -
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2009
[PDF 72KB] -
Notice Regarding Dividend and the Difference between Dividend Forecast
[PDF 40KB] -
Appointments of Directors
[PDF 17KB] -
Relief Efforts Support for the Devastating Big Earthquake Disaster Area in Republic of Haiti
[PDF 123KB] -
Chugai Renews its Website for the First Time in Six Years
[PDF 359KB] -
ACTEMRA®,a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,Approved in the United States for Rheumatoid Arthritis
[PDF 118KB]